Concurrent hyperglycemia does not influence the long-term prognosis of unresectable hepatocellular carcinomas

Table 4 Association between various clinical parameters after treatment and the survival

Clinical status		n	Cumulative survival rate (%)			Median survival ( ± SE, months)	P value
			1-year	2-year	3-year
Overall		225	58.5	30.6	9.4	28.0 ± 1.40
Age (year)	< 60	130	59.4	27.4	9.1	28.1 ± 2.37
	≥ 60	95	57.3	35.4	9.7	26.8 ± 2.60	0.815
HBV	Negative	100	61.8	31.2	9.69	29.3 ± 2.01
	Positive	125	54.4	29.9	8.97	26.1 ± 3.63	0.876
AFP (ng/ml)	<400	129	66.1	34.4	10.9	30.0 ± 2.38
	≥ 400	96	47.8	25.4	6.9	22.2 ± 4.05	0.001
Hyperglycemia	Negative	28	51.1	30.7	8.36	26.0 ± 3.46
	Positive	197	59.7	30.5	9.62	29.5 ± 2.04	0.231
Tumor size (cm)	< 6 cm	124	67.4	38.1	12.1	31.7 ± 1.99
	≥ 6 cm	101	47.0	19.9	5.42	21.0 ± 3.55	0.028
Number of tumors	Solitary	152	67.6	34.7	10.4	29.3 ± 1.40
	Multiple	73	52.0	21.3	7.1	25.8 ± 4.73	0.041
Child pugh	A	187	65.1	34.7	11.1	31.0 ± 1.65
	B or C	38	28.4	9.5	0	12.1 ± 2.49	0.002
Clinical	Non-T4 disease	121	69.5	39.3	15.3	32.1 ± 1.13
stage	T4 disease	104	44.6	18.6	1.43	20.9 ± 2.17	0.018
Method of treatment	TACE	181	56.4	27.1	8.48	26.8 ± 1.43
	Radiotherapy	23	58.3	29.2	4.17	32.6 ± 9.85
	TACE+ radiotherapy	21	77.8	63.0	25.2	37.8 ± 6.62	0.0001